Sunpharma FY24 Annual Earnings Summary

Supplies from Mohali have not resumed; residual inventory sales are declining. Market share loss may be permanent depending on competition and contracts.

Halol plant remains under FDA scrutiny; no timeline for re-inspection or resolution, impacting US generic supply.

Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.

The $43/share offer requires approval from Taro's minority shareholders; failure could derail the merger.

OAI status and 483 observations at Mohali and Dadra facilities could impact US generic launches and revenue.

India market share fell to 8.33% from 8.5% due to NLEM price cuts and sitagliptin patent expiry. Recovery timeline uncertain.

Management provided no update on the Taro minority buyout beyond forming a special committee. Strategic benefits remain unclear.

Multiple Phase II/III trials (ILUMYA PsA, deuruxo, GLP-1) require significant investment. Failure or delay could impact returns.

Taro's operations in Israel may be impacted by regional conflict, though management says business continuity is maintained.

Management sees no significant improvement in generic pricing environment; pricing remains product-specific and competitive.

CEQUA's market share has declined due to generic Restasis and new entrants with different mechanisms of action.

Management is monitoring the Red Sea situation; potential for shipment delays if situation does not normalize.